Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.

Background: Bacillus Calmette-Guérin (BCG) instillation is regarded as the most effective bladder-sparing treatment for patients with high-grade T1 tumours and carcinoma in situ (CIS). The major problem with this therapy is the side-effects, making maintenance therapy difficult, even impossible, in a proportion of patients. Thus, alternative schedules and drugs have been proposed.

Results of second-look resection after primary resection of T1 tumour of the urinary bladder.

Objective: To study residual tumours at second-look resection in patients resected 4-8 weeks earlier for T1 tumours of the urinary bladder.

Material And Methods: All patients randomized in the ongoing Nordic T1G2-G3 Bladder Sparing Study with monitored data available were included in the study. Data on residual tumours at second-look resection were compared to basic patient and tumour characteristics.

Informed consent for clinical education--randomized study of two different strategies at a urology surgery.

Objective: To study whether or not the provision of written information in advance might influence patients' inclination to participate in the clinical education of medical students at a urology surgery.

Material And Methods: A total of 169 outpatients referred to the urological surgery were randomly allocated either to receive information in advance or not, together with a notice of appointment that all patients receive by mail approximately 2 weeks prior to their visit. Patients in the experimental group received a written information letter in advance about medical education, whereas the control patients did not receive any written information, according to the standard procedure of the surgery.

Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study.

Objectives: To evaluate whether, in patients with carcinoma in situ (CIS) of the urinary bladder, alternating instillation therapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) was more effective and less toxic than conventional BCG monotherapy.

Methods: Patients were stratified prospectively for primary, secondary, and concomitant CIS and randomized to one of two regimens. Patients in the alternating group received six weekly intravesical instillations of MMC 40 mg, followed by alternating monthly instillations of BCG 120 mg and MMC for one year.